OctoPlus Enters Development & Manufacturing Agreement With Ferring Pharmaceuticals
OctoPlus N.V. recently announced a formulation development and manufacturing contract has been signed with Ferring Pharmaceuticals A/S, a leading innovative pharmaceutical company. The undisclosed contract value will make a material contribution to OctoPlus’ 2012 revenues. Further details on the compound and activities are not disclosed.
OctoPlus is a specialty pharmaceutical company focused on the development and manufacture of improved injectable pharmaceuticals based on its proprietary drug delivery technologies that exhibit fewer side effects, improved patient convenience, and a better efficacy/safety balance than existing therapies. OctoPlus also focuses on the development of long-acting, controlled-release versions of known protein therapeutics, peptides, and small molecules, including specialty generics.
The clinically most advanced product incorporating its technology is Locteron, a controlled-release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October 2008. Locteron is being manufactured for Biolex by OctoPlus and has recently completed Phase IIb clinical studies with superior clinical data versus current treatment.
In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical-scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.
Total Page Views: 1204
